Table 3.

SMRs with 95% CIs by risk group, clinical stage at baseline and CD4 cell count and viral load at 6 months based on 29 935 patients

		Clinical stage at baseline A/B		Clinical stage at baseline C
Risk group	6-month CD4 count (cells/μL)	6-month viral load ≤500 copies/ml	6-month viral load >500 copies/ml	6-month viral load ≤500 copies/ml	6-month viral load >500 copies/ml
MSM	0–49	3.41 (0.85–13.7)	23.4 (13.0–42.2)	9.62 (5.80–16.0)	24.91 (16.55–37.48)
	50–99	3.23 (1.68–6.21)	6.59 (2.96–14.7)	4.98 (3.28–7.57)	13.40 (7.93–22.62)
	100–199	2.27 (1.57–3.29)	3.52 (2.09–5.95)	3.29 (2.32–4.65)	6.92 (4.24–11.29)
	200–349	1.47 (1.07–2.01)	3.50 (2.33–5.27)	2.65 (1.79–3.93)	1.92 (0.80–4.61)
	≥350	1.05 (0.82–1.35)	2.06 (1.37–3.10)	1.73 (1.01–2.98)	2.48 (0.93–6.61)
Heterosexuals	0–49	8.40 (4.65–15.16)	28.03 (17.2–45.8)	11.2 (6.72–18.5)	25.7 (18.5–35.8)
	50–99	4.34 (2.62–7.21)	2.11 (0.68–6.53)	4.24 (2.70–6.64)	12.16 (7.33–20.2)
	100–199	2.18 (1.50–3.18)	3.59 (2.26–5.69)	2.91 (1.99–4.24)	5.25 (3.16–8.71)
	200–349	1.85 (1.35–2.53)	3.26 (2.03–5.24)	2.25 (1.40–3.62)	4.67 (2.59–8.44)
	≥350	1.33 (1.00–1.75)	1.88 (1.11–3.17)	2.52 (1.36–4.69)	3.91 (1.63–9.39)
IDUs	0–49	19.1 (9.09–40.0)	73.7 (46.4–116.9)	13.5 (6.43–28.30)	52.8 (35.4–78.7)
	50–99	6.31 (3.15–12.6)	20.6 (11.7–36.3)	13.0 (6.47–25.89)	40.5 (23.0–71.3)
	100–199	10.3 (7.00–15.1)	14.6 (9.29–22.8)	8.56 (5.07–14.45)	20.5 (12.2–34.7)
	200–349	6.44 (4.55–9.10)	15.1 (10.4–22.1)	7.40 (4.20–13.03)	14.6 (7.29–29.2)
	≥350	5.59 (4.28–7.29)	8.31 (5.42–12.7)	9.39 (5.33–16.54)	24.9 (11.2–55.4)

Standardized mortality ratios (95% confidence intervals).